Abstract | Hypoxia-inducible factors (HIFs) are broadly expressed in human cancers, and HIF1α and HIF2α were previously suspected to promote tumour progression through largely overlapping functions. However, this relatively simple model has now been challenged in light of recent data from various approaches that reveal unique and sometimes opposing activities of these HIFα isoforms in both normal physiology and disease. These effects are mediated in part through the regulation of unique target genes, as well as through direct and indirect interactions with important oncoproteins and tumour suppressors, including MYC and p53. As HIF inhibitors are currently undergoing clinical evaluation as cancer therapeutics, a more thorough understanding of the unique roles performed by HIF1α and HIF2α in human neoplasia is warranted.
Oxygen (O 2 ) concentrations are known to vary substan tially in a solid tumour, owing to rapid cell division and aberrant tumour angiogenesis and blood flow. Although extended exposure to complete O 2 deprivation (anoxia) can result in necrosis, viable hypoxic cancer cells often surround necrotic zones. Tumour hypoxia has long been associated with increased malignancy, poor prog nosis and resistance to radiotherapy and chemotherapy (reviewed in REFS 1, 2) , prompting intensive research into cellular responses to O 2 deprivation. Particular interest has been focused on the mechanisms by which hypoxic tumour cells alter their transcriptional profiles to modu late glycolysis, proliferation, survival and invasion to persist under conditions of hypoxic stress 3 . The hypoxiainducible factor (HIF) transcription factors mediate the primary transcriptional responses to hypoxic stress in normal and transformed cells. HIFs are basic helix-loop-helix-PER-ARNT-SIM (bHLH-PAS) pro teins that form heterodimeric complexes that are com posed of an O 2 labile αsubunit (HIF1α, HIF2α (encoded by EPAS1) or HIF3α) and a stable βsubunit (HIF1β; also known as ARNT). Together, these subunits bind hypoxia responsive elements (HREs) that contain a conserved RCGTG core sequence (BOX 1) . Hypoxic HIF activity is controlled primarily through posttranslational modifi cation and stabilization of HIF1α and HIF2α subunits, so that HIFα protein levels and overall HIF transcrip tional activity increase as cells become more hypoxic. The central molecular mechanisms underlying the O 2 lability of HIFα subunits were first described in 2001 by multiple groups and are the subject of several recent reviews 4, 5 . Briefly, HIFα subunits are modified by HIFspecific pro lylhydroxylases (PHDs) in the presence of O 2 , which leads to normoxic proteasomal degradation that is medi ated in part by the von Hippel-Lindau (VHL) tumour suppressor protein. It is also important to note that increased oncogenic signalling in cancer cells can induce the expression of HIFα subunits through O 2 independent mechanisms that include increased transcription and/or translation of HIFα mRNAs 6 . HIF1α was first described by Semenza and col leagues 7 in 1995, when it was shown to have a central role in mediating O 2 dependent transcriptional responses. In 1997, the identification by independent groups of HIF2α -which was initially called endothelial PAS protein 1 (EPAS1) 8 , HIFrelated factor (HRF) 9 , HIF1αlike fac tor (HLF) 10 or member of PAS family 2 (MOP2) 11 indicated that HIF regulation was more complex. Whereas HIF1α seems to be expressed in nearly all cell types, RNA in situ hybridization of mouse embryos revealed that the expression of Epas1 is more restricted and is particularly abundant in blood vessels. This obser vation led to the hypothesis that the primary role of HIF2α is to modulate vascular endothelial cell function, an idea that is supported in part by the close correlation of the mRNA expression patterns of EPAS1 and vascular Nature Reviews | Cancer 
ARNT
The aryl hydrocarbon receptor nuclear translocator (ARNT) was originally identified as the binding partner for the aryl hydrocarbon receptor (AHR). ARNT was later shown to be identical to HIF1β, the obligate binding partner for HIF1α and HIF2α.
endothelial growth factor A (VEGFA) 8 . A more complex view emerged as HIF2α protein expression was identi fied in multiple cell types in hypoxic rat kidney, lung and colonic epithelia, as well as in hepatocytes, macrophages, muscle cells and astrocytes 12 , indicating that both HIF1α and HIF2α are coexpressed in many cell types.
Most HIF transcriptional responses have been attrib uted to HIF1α and HIF2α; however, a third HIFα subunit (HIF3α) has also been described 13 . HIF3A mRNA is dif ferentially spliced to produce multiple HIF3α isoforms that either promote or inhibit the activity of other HIF complexes, although little is currently known about the impact of HIF3α on tumour progression in hypoxic con ditions [14] [15] [16] [17] . Similarly, ARNT2 has been identified 18 and shown to regulate neuronal development 19 and to exhibit overlapping activity with HIF1β 20 ; however, its activity in human cancer cells has not been studied in depth 21 . Although it will be important to determine whether (and how) HIF3α and ARNT2 affect HIFmediated responses in cancers, the available evidence suggests that HIF1α and HIF2α (together referred to as HIFα hereafter) account for the vast majority of HIFdependent effects on tumour growth and progression that have been described to date.
Increased expression of HIF1α and HIF2α has been observed in a broad range of human cancer cell types, and has been associated with poor prognosis in many cases (TABLE 1) . Particular attention has been focused on renal cell carcinomas (RCCs), approximately 90% of which lose the function of VHL, which binds prolyl hydroxylated HIFα subunits and targets them for ubiquitinmediated proteolysis 22 
. The basis for these apparent discrepancies is not understood, but may reflect the consequences of HIF activity in different cancer sub types or at different stages of tumour progression. In some tumours, including gastric cancers and glioma, only one HIFα subunit is correlated with prognosis, suggest ing that it has a particularly important or predominant role in these tumour cell types.
Interestingly, multiple recent studies have also revealed unexpected tumoursuppressive activities of HIF1α and HIF2α in specific contexts [23] [24] [25] [26] . Although initially viewed as having largely overlapping functions, there is now mounting evidence that HIF1α and HIF2α can promote highly divergent, even opposing, outcomes
At a glance
• Hypoxia-inducible factor 1α (HIF1α) and HIF2α are broadly expressed in many human cancers, and expression of these proteins frequently correlate with poor patient prognosis.
• Although HIF1α and HIF2α share some redundant functions, they also exhibit unique and even opposing activities in cell growth, metabolism, angiogenesis, nitric oxide homeostasis and other processes that affect tumour growth.
• A careful genetic dissection of Hif1a versus Epas1 (which encodes HIF2α) in autochthonous mouse models of cancer is underway, but is only in its infancy. Given that recent results have revealed unanticipated roles for the HIFα subunits in these assays, more work is clearly needed.
• The HIFs affect many key aspects of tumour initiation, progression, invasion, inflammatory cell recruitment and metastasis; therefore, they represent attractive targets for novel targeted therapies.
• Surprisingly, HIF1α can function as a tumour suppressor in renal cell carcinoma, whereas HIF2α functions as a tumour suppressor in lung adenocarcinoma. Because HIF inhibitors are being developed for therapeutic benefit, possible tumour-suppressive roles for the HIFs in a minority of human cancers should be carefully assessed.
Box 1 | O 2 -dependent regulation of HIF
Using molecular oxygen (O 2 ) and 2-oxoglutarate as substrates, hypoxia-inducible factor (HIF) prolyl-hydroxylase (PHD) enzymes 4 hydroxylate two specific proline residues in the O 2 -dependent degradation domain (ODD) of HIFα proteins (see the figure) . These hydroxylation events occur on Pro402 and Pro564 in HIF1α, and Pro405 and Pro531 in HIF2α, and are required for the von Hippel-Lindau (VHL) tumour suppressor protein -the recognition component of an E3 ubiquitin ligase complex -to bind and degrade HIFα subunits under normoxic conditions. Hypoxia inhibits PHD activity through various mechanisms, including substrate limitation (reviewed in REF. 4 ), which results in HIFα subunit stabilization, heterodimerization with HIF1β (also known as ARNT), and increased HIF transcriptional activity. Hypoxic conditions also inhibit hydroxylation by factor inhibiting HIF (FIH) of a conserved carboxy-terminal asparagine residue in the HIFα subunits, an event that blocks the interaction between HIFα subunits and the transcriptional co-activators p300 and CREB binding protein (CBP) [149] [150] [151] . Thus, whereas PHD-mediated hydroxylation destabilizes HIFα subunits, FIH-mediated hydroxylation inhibits their transcriptional activity. bHLH, basic helix-loop-helix; PAS, PER-ARNT-SIM; TAD, transactivation domain.
Autochthonous
This term means 'originating where found' . It refers to tumours that arise in the tissues in which they are usually detected; for example, thymic lymphomas developing in the thymus of genetically engineered animals.
when expressed in the same cell type. It seems that HIF1α and HIF2α mediate these disparate responses partly through independent regulation of distinct target genes, but also through direct and indirect interactions with complexes that contain important oncoproteins and tumour suppressors.
Gene expression by HIF1α and HIF2α
Numerous early studies revealed that either HIF1α or HIF2α could regulate the expression of many of the same hypoxiainduced genes, but that each HIFα also had unique targets 27, 28 (TABLE 2) . By swapping protein domains between HIF1α and HIF2α, several groups dem onstrated that this transcriptional specificity resides in the aminoterminal transactivation domain (NTAD), sug gesting that differential interactions with transcriptional co factors probably determine differential gene activa tion 29, 30 . Recently, multiple groups have used chromatin immuno precipitation coupled to tiled microarrays (ChIPchip) to assess the binding of HIFα subunits across the genome [31] [32] [33] [34] [35] . These analyses confirmed the RCGTG core binding sequence and revealed no additional sequences that are absolutely required for HIF binding 32, 35 . Direct comparison of HIF1α and HIF2α binding in MCF7 breast cancer cells demonstrated that although some sites bind HIF1α exclusively, many others bind HIF1α and HIF2α with equal affinity, despite the fact that HIF2α contributes to the hypoxic expression of relatively few genes in these cells 33 . A subsequent highresolution analysis using ChIP followed by high throughput sequencing (ChIP-seq) revealed that the HIFs bind to approximately 500 highaffinity sites across the genome, many of which are located at great distances (>100 kb) from the genes that they regulate 35 . Perhaps not surprisingly, HIF1α and HIF2α were shown to bind preferentially to the specific genes that each is known to preferentially regulate (TABLE 2) . For example, a sig nificantly higher level of HIF1α binding was associated with glycolytic pathway genes, whereas relatively greater HIF2α binding was observed at the POU5F1 locus (which encodes OCT4). Strikingly, however, significant levels of both proteins were detected at essentially all HIF binding sites, which further implicates differential interactions with specific cofactors, perhaps mediated by distinct posttranslational modifications, in control ling target gene specificity 35 . Interestingly, it seems that HIFs are recruited to genes that are already expressed in normoxic cells (as revealed by DNase I hypersen sitivity) and are therefore unlikely to direct hypoxia induced changes in the chromatin structure of target genes 32, 35 . The range of HIF target genes may therefore be determined largely by underlying celltypespecific patterns of chromatin structure, a speculation that is supported by the limited concordance (40-60%) between the HIF binding sites detected in MCF7 and RCC cells 35 . Intriguingly, several reports indicate that HIF1α binds to, and regulates the expression of, mul tiple Jumonjidomaincontaining histone demethylases (JMJHDs), which might contribute directly to hypoxiamediated changes in target gene expression 31, 34 .
HIF1α and HIF2α function in tumour models
Multiple xenograft tumour models (TABLE 3) support the hypothesis that HIF1α and HIF2α promote tumour progression by regulating both shared and unique target genes. As deletion of Hif1a in mice results in lethality at embryonic day (E) 9.5 (REFS 36, 37) , and HIF2α deficiency causes embryonic and perinatal lethality [38] [39] [40] or severe developmental abnormalities 41 , conditional alleles 37, 42 are required to investigate the specific effects of HIFα deficiencies in autochthonous mouse tumour models. Only a few studies have been reported to date (TABLE 3) , but these have demonstrated independent roles for HIF1α and HIF2α in different cancers, as well as stromal cell types, at various stages of tumour growth and progression. For example, the deletion of Hif1a in a mouse mammary tumour virus (MMTV) promoterdriven polyoma middle T antigen mouse model of breast cancer reduced the initial growth of the primary tumours. However, by the time the mice were sacrificed equivalent tumour burdens were evident in the Hif1a flox/flox and Hif1a -/-mice. Importantly, deletion of Hif1a significantly reduced the number of pulmonary metastases 43 (TABLE 3) . 26 . This latter effect correlated with HIF2αdriven expression of Scgb3a1, which encodes the putative tumour suppressor secretoglobin 3A1 (REF. 44) . Surprisingly, overexpression of a stabilized HIF2α pro tein in the same KRAS lung tumour mouse model also promoted tumour angiogenesis and tumour invasion by increasing the expression of VEGFA and SNAIL 45 , respectively. The observation that either HIF2α overex pression or deletion can promote tumour growth in the same tumour context, albeit by different mechanisms, suggests that effective targeting of HIFα subunits in can cer treatment may be challenging. Similarly, the growth of VHLdeficient mouse liver haemangiomas was shown to be specifically dependent on HIF2α, but not HIF1α 46 . The deficiency of HIF1α or HIF2α in tumourassociated stromal cells has also revealed isoformspecific effects on cancer progression (FIG. 1) . Initial gene expression studies revealed independent effects of HIF1α and HIF2α in pri mary human macrophages and cultured murine macro phages 47 . Hif1a deletion in macrophages reduced overall tumour growth in a mouse model of breast cancer by reducing the expression of inducible nitric oxide synthase (iNOS; also known as NOS2) and consequently reducing the production of NO, (which inhibits T cell responses in vitro and immune surveillance in vivo) 48 . Intriguingly, HIF2α drives the expression of arginase 1 in macrophages (REF. 49 ). This enzyme catabolizes larginine and so reduces the availability of this substrate for NO production. HIF1α and HIF2α therefore seem to oppose one another to properly regulate the overall concentrations of NO in macro phages. Interestingly, the deletion of Epas1 (but not Hif1a) in mouse macrophages also significantly inhibits the expression of cytokine and chemokine receptors, including the macrophage colonystimulating factor 1 receptor (MCSFR; also known as CSF1R) and CXCR4 (REF. 50 ). This has the effect of limiting the migration of macrophages into autochthonous liver and colorectal cancers and reduces the overall tumour burden.
Loss of either HIF1α or HIF2α in mouse vascular endothelial cells reduced tumour expansion in xeno graft models, although through different mechanisms. Endothelialcellspecific Hif1a deletion reduced VEGF receptor 2 (VEGFR2) expression, thereby inhibiting VEGF signalling and endothelial cell proliferation, survival and expansion in hypoxic zones of tumours 51 . By contrast, loss of HIF2α function in endothelial cells reduced the expression of ephrin A1 (REF. 52 ), Delta like 4 (DLL4) and angiopoietin 2 (ANGPT2) 53 , which correlated with unproductive vessel sprouting, aber rant vessel remodelling and reduced xenograft tumour growth. Collectively, these results reveal complex roles for HIF1α and HIF2α in distinct tumour and stromal cell types, although it will be important to test their functions in additional tumour models.
Differential regulation of HIFα expression
What molecular mechanisms contribute to the differential regulation of HIF1α and HIF2α? Control of HIF activ ity has been traditionally attributed to the O 2 dependent posttranslational stabilization of HIFα subunits; however, recent data indicate that control of HIF1α and HIF2α expression can be selectively regulated at the levels of transcription, translation and protein stability (FIG. 2a) .
Box 2 | HIFs in normal and cancer stem cells
Stem cells reside in complex microenvironments, or niches, and multiple studies have revealed that oxygen (O 2 ) concentrations influence the ability of stem and/or progenitor cells to remain quiescent or to undergo differentiation, depending on the cell type 152 . Hypoxia-inducible factor 1α (HIF1α) and HIF2α exhibit distinct roles in stem cell regulation. HIF1α seems to have a dominant role in modulating WNT-β-catenin signalling in hypoxic embryonic stem cells and isolated neural stem cells (NSCs) of the embryonic mesencephalon and adult hippocampus 153 . WNT-β-catenin activity is closely associated with regions of low O 2 concentrations in the subgranular zone of the hippocampus, an important NSC niche, and Hif1a deletion impairs WNT-dependent processes, such as NSC proliferation, differentiation and neuronal maturation. It should be noted that the opposite result has been reported for colon cancer cells, in which HIF1α inhibits WNT-β-catenin activity 154 , indicating that the interaction between HIF1α and WNT in stem cells is functionally distinct from more differentiated cells, including neoplastic cells. However, the basis for this difference is currently unknown. HIF1α has also been proposed to increase the intracellular stability of activated NOTCH1 and to promote the induction of NOTCH target genes in myogenic and neural precursor cells 155 . This has been extended to thymic lymphomas in p53 mutant mice in which HIF1α promotes NOTCH1 activation and target gene expression 156 . However, data from neuroblastoma stem cells suggest that both HIF1α and HIF2α can augment NOTCH pathway signalling 157 . By contrast, HIF2α (but not HIF1α) regulates the POU transcription factor OCT4 (also known as POU5F1) 158 . OCT4 is essential for maintaining an undifferentiated cell fate in embryonic stem cells, the embryonic epiblast and primordial germ cells. Finally, HIF2α is selectively expressed in CD133 + glioblastoma 'cancer stem cells', whereas HIF1α is detected in both tumorigenic (that is, stem) and non-tumorigenic populations, suggesting that HIF2α has a unique role in the CD133 + subpopulation 69 . Similarly, human neuroblastomas have small numbers of tumour-initiating or stem-like cells that express neural crest markers (ID2, NOTCH1, HES1 and vimentin) and HIF2α
157
. On HIF2α inhibition, these cells undergo early differentiation into sympathetic neuronal cells and express markers such as achaete-scute homologue 1 (ASH1), ISL1 and stathmin-like 2 (also known as SCG10). It is noteworthy that the CD133 + glioblastoma and putative neuroblastoma tumour initiating or stem-like cells express high levels of HIF2α, although they reside in peri-endothelial niches 159 . Although the extent of O 2 saturation within these capillaries is unknown, the data are consistent with the idea that HIF2α accumulates at higher concentrations of O 2 than does HIF1α. Alternatively, the expression of HIFα subunits in distinct cancer cell subpopulations could be controlled by non-hypoxic stimuli, such as aberrant metabolism 160 .
Differential transcription. Surprisingly, relatively little is known about the transcriptional regulation of the HIF1A and EPAS1 genes. Nuclear factorκB (NFκB) regulates the transcription of HIF1A [54] [55] [56] [57] . Moreover, helper T cell (T H )1 cytokines stimulate this NFκB-HIF1α pathway to activate a range of HIF1α target genes, whereas the T H 2 cytokines interleukin4 (IL4) and IL10 differen tially activate EPAS1 expression 49 , although the precise mechanisms involved are not clear. Expression at the HIF1A locus, in contrast to the EPAS1 locus, is also regulated by the SWI/SNF chromatin remodelling pro tein BRG1associated factor 57 (BAF57; also known as SMARCE1) 58 . Additional investigation into differential HIF1A and EPAS1 transcription is certainly warranted.
Differential mRNA translation. It is well established that increased rates of HIFα mRNA translation increase HIFα protein levels and activity, particularly in cells with activated PI3K-AKT-mTOR signalling, which is a common feature of cancer cells (reviewed in REF. 6 ). Intriguingly, HIF1α expression in RCC cell lines seems to be regulated by both of the kinase complexes mTOR complex 1 (mTORC1) and mTORC2, whereas HIF2α expression is mTORC2dependent and mTORC1 independent 59 . Other forms of differential translation control have been reported for HIFα proteins 60, 61 . For example, the iron response element (IRE) binding pro tein 1 (IREBP1; also known as aconitase) was shown to bind a canonical IRE in the 5′ untranslated region (UTR) of EPAS1, thereby inhibiting its translation 61 . This effect seems to be specific for HIF2α, as IREBP1 fails to bind the HIF1A transcript or regulate its translation, despite the presence of a nearconsensus IRE in the 5′ UTR of HIF1A 62 . This regulation is also consistent with the identifica tion of HIF2α as the primary regulator of erythropoiesis and cellular iron metabolism in vivo 42, [63] [64] [65] [66] . (similar results were later reported for glioma cells 69 ). Hypoxic neuroblastoma cells 68 and lung adenocarci noma cells 60 maintain increased HIF2α levels during longterm (48 hours) culture in hypoxic conditions; by contrast, HIF1α levels increase acutely on exposure to hypoxia, but then decline after several hours. The HIF mediated expression of antisense transcripts from the HIF1A locus, but not the EPAS1 locus, results in HIF1A mRNA destabilization and might explain the gradual and specific reduction of HIF1α protein levels 60 . Two HIF1αspecific E3 ubiquitin ligases have been described recently that might also contribute to the dif ferential stability of HIF1α and HIF2α. HIFassociated factor (HAF) binds and destabilizes HIF1α under nor moxic and hypoxic conditions in a VHLindependent, proteasomedependent manner, but has no effect on HIF2α levels 70 . Instead, HAF binds HIF2α at a distinct carboxyterminal region and promotes HIF2α transcrip tional activity, effectively switching cells from a HIF1α to a HIF2α transcriptional programme 71 . In addition, heat shock protein 70 (HSP70) and carboxyl terminus of HSP70interaction protein (CHIP), a recently identified E3 ubiquitin ligase, were shown to bind and degrade HIF1α but not HIF2α under conditions of prolonged hypoxia in cultured cells, whereas rapid reoxygenation destabilized both HIF1α and HIF2α in a PHD-VHL dependent manner 72 . Precisely how these novel ubiquitylation events are regulated, either by hypoxia or other stimuli, and how they affect HIF activity in cancer progression, is not yet known.
Post-translational modifications of HIFα
HIFα subunits are posttranslationally regulated by the hydroxylation of prolines (catalysed by PHDs) and the hydroxylation of asparagine (catalysed by factor inhib iting HIF (FIH; also known as HIF1AN)) 4, 63, [73] [74] [75] 
Interestingly, specific PHD enzymes exhibit biased activ ity toward HIF1α or HIF2α; for example, PHD3 prefer entially hydroxylates HIF2α in multiple cell lines 76 . Peet and colleagues 77 have also shown that FIH preferentially hydroxylates HIF1α in certain cell lines on the basis of the amino acid that is immediately carboxyterminal to the hydroxylated asparagine: in HIF1α this is valine and in HIF2α this is alanine. These results suggest that dif ferential asparagine hydroxylation might regulate HIF1α and HIF2α activity, although the largely HIFindependent neurological phenotypes of FIHdeficient mice 78 indicate that other factors are probably involved.
In addition to hydroxylation, both HIF1α and HIF2α are subject to a range of distinct, O 2 independent post translational modifications, and growing evidence indicates that at least some of these are specific for either HIF1α or HIF2α, and may promote their differential activity (FIG. 2b) .
Phosphorylation. Early work showed that both HIF1α and HIF2α are phosphorylated 79, 80 , and recent work sug gests that isoformspecific phosphorylation may affect tumour progression. Specifically, Huang and colleagues 81 demonstrated that HIF1α represses the MYCdependent expression of the DNA damage response protein nibrin (NBN; also known as NBS1) by displacing the SP1 tran scription factor from MYC. By contrast, HIF2α is inhib ited from interacting with SP1 through phosphorylation on Thr324 by protein kinase D1 (PKD1; also known as PRKD1), a modification that is dependent on a neigh bouring proline residue that is unique to HIF2α (FIG. 2c) . When a proline residue was introduced into the corre sponding position in HIF1α, PKD1 also phosphorylated this HIF1α mutant, which consequently lost the ability to displace SP1 from MYC 81 . Other specific phospho rylation events catalysed by MAPK 82 , casein kinase 1 (CK1) 83 and ataxia telangiectasia mutated (ATM) 84 have been shown to modulate HIF1α activity, although it is not yet known whether HIF2α is also a substrate of these kinases. It will be important to determine the degree to which these various phosphorylation events distinguish HIF1α and HIF2α activation, and whether they represent another mechanism of parallel regulation in cancer cells.
Acetylation. The activity of HIFα proteins is also modulated by multiple sirtuins, a family of redox sensitive, NAD + dependent deacetylases and/or ADP ribosyltransferases. Mammalian cells express a family of sirtuins (SIRT1-7) that regulate complex changes in gene expression, metabolism and the cellular redox sta tus; they have also been implicated in controlling lon gevity, although this idea remains highly controversial 85 . SIRT1 forms a complex with HIF2α and deacetylates con served lysine residues in the NTAD, and this deacetyla tion enhances HIF2α transcriptional activity in vitro and in vivo 86 . SIRT1 was also reported to deacetylate lysine residues in HIF1α, which resulted in HIF1α transcrip tional repression 87 , although this effect was not universally observed 86 (FIG. 3) .
The apparently opposing effects of SIRT1 on HIF1α and HIF2α could skew cells toward either HIF1α or HIF2α transcriptional programmes in response to changing metabolic activity in hypoxic tumours. Park and colleagues 87 proposed a positive feedback mecha nism in which HIF1α promotes glycolysis, thus decreas ing NAD + /NADH ratios and inhibiting SIRT1 under hypoxic conditions, thereby further augmenting the activity of HIF1α. Presumably, inhibiting SIRT1 under these conditions would also decrease HIF2α activity, although the relative sensitivity of endogenous HIF1α and HIF2α proteins to SIRT1mediated effects over a range of O 2 concentrations is not yet clear, and the kinet ics of these responses may differ. It would be interesting to determine whether deacetylation by SIRT1 contrib utes to the high relative abundance of HIF2α at inter mediate O 2 concentrations. There seem to be yet more wrinkles in this story, as both HIF1α and HIF2α were shown to bind the SIRT1 promoter and to induce SIRT1 expression under hypoxia 88 , and AKT activity can induce the expression of both HIF1α and SIRT1 by downregulating expression of the microRNA miR199a5p 89 . Other sirtuins have also been shown to regulate the activity of HIFα. Mostoslavsky and colleagues 90 identi fied SIRT6 as a HIF1α repressor, and showed that SIRT6 deficiency increased HIF1αdependent glucose uptake and glycolytic activity at the expense of mitochondrial respiration. Although the precise mechanisms that regu late interactions between SIRT6 and HIF1α are not yet clear, SIRT6 deficiency increases both the synthesis and stability of HIF1α, suggesting that the effects of SIRT6 might be partly indirect. In addition, the mitochondrial deacetylase SIRT3 indirectly regulates HIFα stabilization by suppressing the formation of mitochondrial reactive oxygen species (ROS) 91 , which in turn promote the sta bilization of HIF1α [92] [93] [94] . For this reason, SIRT3deficient cells have HIF1αdependent increases in glucose trans port, glycolysis and proliferation 95, 96 . The implications of these findings for tumour progression have not been explored in depth, but are likely to be both complex and important.
It is possible that other acetylation and deacetylation events regulate HIF activity. For example, in mice, arrest defective 1 (ARD1; also known as NAA10) was reported to destabilize HIF1α by acetylating Lys532 (REF. 97 ), an event that is apparently reversed by the recruit ment of histone deacetylase 1 (HDAC1) to HIF1α by metastasisassociated protein 1 (MTA1) 98 . By con trast, other researchers observed neither an interaction between ARD1 and HIF1α, nor any effects of hypoxia on ARD1 activity, so the importance of this regulatory event remains in dispute 99 . Finally, a growing number of reports indicate that HIFα proteins are subject to numer ous other posttranslational modifications, including sumoyl ation, Snitrosylation, and neddylation [100] [101] [102] [103] [104] [105] [106] , although whether any of these modifications differentially regulate HIF1α and HIF2α is as yet unknown. (TABLE 2) , recent evidence indicates that these HIFα proteins also affect tumour pro gression by exerting distinct, often opposing, effects on crucial oncoproteins and tumour suppressors, including MYC, p53 and mTOR.
HIFα and MYC. In many cell types, hypoxia suppresses proliferation. Koshiji et al. 107 were the first to show that acute HIF1α stabilization at 1% O 2 produces cell cycle arrest by inhibiting MYC, a bHLH-leucine zipper (LZ) transcription factor that is overexpressed in >40% of human cancers. MYC controls the G1/S cell cycle tran sition by forming heterodimers with a related protein MAX. This heterodimer binds to conserved Ebox sequences (CTCGAG), thus promoting the expression of genes such as cyclin D2 (CCND2), E2F1 and ornithine decarboxylase 1 (ODC1). MYC simultaneously inhib its the expression of CDKN1A and CDKN1B -which encode the cyclindependent kinase inhibitors (CDKIs) p21 and p27, respectively 108 -in part by displacing SP1 from the transcription factor MYCinteracting zinc fin ger protein 1 (MIZ1; also known as ZBTB17). MYC also promotes proliferation and cell growth by inducing the expression of almost all glycolytic enzymes and enhancing protein synthesis.
Under hypoxic conditions, HIF1α binds to SP1, thus displacing MYC from multiple target genes, includ ing CDKN1A, MSH2, MSH6 and NBN 81, 109 (FIG. 4) .
Gordan et al. 110 subsequently showed that HIF1α can rapidly disrupt the association of MYC with MAX and MIZ1, thus reducing MYC promoter occupancy at the CDKN1A, CDKN1B, CDKN2B (which encodes p15), ODC1, CCND2 and E2F1 genes. A more chronic adap tation results from HIF1αmediated induction of the expression of MAX interactor 1 (MXI1), which inter acts with MAX at Eboxes to inhibit the expression of ODC1 and peroxisome proliferatoractivated receptorγ coactivator 1β (PPARGC1B) 111, 112 ; this leads to the sup pression of mitochondrial biogenesis and function. Moreover, HIF1α promotes MYC degradation under conditions of chronic hypoxia 111, 112 . Through these multiple mechanisms, HIF1α effectively limits MYC dependent anabolic metabolism, protein synthesis and cell division, all of which are important adaptations to hypoxia. Intriguingly, HIF1α also drives the expression of glycolytic pathway genes, which permits hypoxic cells to inhibit MYCdriven macromolecular synthesis while producing ATP from glycolysis.
Surprisingly, transformed cells expressing HIF2α exclusively exhibit enhanced MYC activity, with more rapid entry into S phase of the cell cycle, increased expres sion of CCND2, E2F1 and ODC1 and increased occu pancy of MYC at these promoters 110 . Moreover, HIF2α (HIF1α) and HIF2α at the levels of transcription or mRNA stability (shown in orange), mRNA translation (shown in blue) and protein stability (shown in purple). In most cases, these regulatory events have opposite effects on HIF1α and HIF2α expression, or seem to be specific for only one HIFα isoform. b | A summary of phosphorylations (P), acetylations (A) and hydroxylations (OH) of HIF1α and HIF2α by casein kinase 1 (CK1), arrest defective 1 (ARD1), prolyl hydroxylases (PHDs), factor inhibiting HIF (FIH), MAPK, sirtuin 1 (SIRT1), protein kinase D1 (PKD1) and ataxia-telangiectasia mutated (ATM). It should be noted that ARD1 acetylates HIF1α, whereas SIRT1 deacetylates both HIF1α and HIF2α. c | Sequence alignment of HIF2α residues 301-331 with a similar region of HIF1α; shaded residues are unique to HIF2α and allow the selective phosphorylation of HIF2α Thr324 by PKD1. BAF57, BRG1-associated factor 57; bHLH, basic helix-loop-helix; CHIP, carboxyl terminus of HSP70-interaction protein; HAF, HIF-associated factor; HSP70, heat shock protein 70; IFNγ, interferon-γ; IL-4, interleukin-4; IREBP1, iron response element binding protein 1; mTORC, mTOR complex; ODD, O 2 -dependent degradation domain; PAS, PER-ARNT-SIM; TAD, transactivation domain. Nature Reviews | Cancer . Of note, RCC cells exclusively expressing HIF2α also displayed reduced genomic instability, which cor related with increased MYCdependent expression of genes encoding DNA repair proteins (including BRCA1, BRCA1associated RING domain protein 1 (BARD1), XRCC2, BUB1 and centro mere pro tein E (CENPE)) 113 . These results reveal a crucial col laborative role for HIF2α and MYC in promoting genomic integrity and resistance to replication stress.
How do HIF1α and HIF2α exert these opposing roles on MYC? Multiple mechanisms seem to be involved: for example, the PASB domain of HIF1α mediates binding to SP1, whereas HIF2α fails to do so because this domain in HIF2α is phosphorylated by PKD1, thus blocking the ability of HIF2α to interact with SP1 (REF. 81 ). By contrast, HIF2α forms a complex with MAX, causing a dosedependent stabilization of the MYC-MAX and MYC-MAX-SP1 complexes. This results in increased MYC-MAX binding at CCND2, E2F1, CDKN1A and CDKN1B 110 . These effects occur rapidly and can be detected after only 1-2 hours at 0.5% O 2 , suggesting that they are independent of HIF2α transcriptional activity, which peaks at approximately 16 hours at 0.5% O 2 . A specific role for MXI1 in this differential regulation is currently unclear, as both HIF1α and HIF2α seem to contribute to MXI1 expression in VHLdeficient RCC cells 112 . How the 'competition' between HIF1α and HIF2α is moderated in a given cell type, in terms of their respec tive influence on MYC activity, is equally mysterious at present.
The relative expression levels of MYC and HIFα proteins also have important roles in regulating tumour cell proliferation and metabolism. Many cancer cells exhibit subtle alterations in MYC levels as a conse quence of increased oncogenic signalling, whereas other cells express MYC at high levels owing to chromo some amplifications, translocations and mutations within MYC exons 108 . It seems that, at high expres sion levels, MYC can sequester and tightly bind MAX, thereby overcoming the potential inhibition of MYC by HIF1α 114 . For example, most genes that were induced by ectopic MYC expression were not transcriptionally repressed by hypoxia in a Bcell lymphoma model. However, the picture is more complex, as HIF1α can also cooperate with MYC to induce the expression of specific target genes, including those encoding the glycolytic enzyme hexo kinase 2 (HK2), pyruvate dehydroge nase kinase 1 (PDK1) and VEGFA 114 . Similarly, high levels of NMYC override the HIF1αmediated inhibition of cell cycle progression while cooperating with HIF1α to promote the expression of phosphoglycerate kinase 1 (PGK1), HK2 and lactate dehydrogenase A (LDHA) in neuroblastomas that have MYCN amplification 115 . In summary, when MYC family members are highly overexpressed, they not only overcome the inhibitory effects of HIF1α, but MYC and HIF1α collaborate to favour glycolysis and continued proliferation under decreased O 2 availability. By contrast, tumours with lower MYC levels are susceptible to HIF1αmediated inhibition of MYC, which explains the anti tumorigenic effects of HIF1α in certain cancers, such as RCC 116 .
HIF1α, HIF2α and p53. Low O 2 concentrations and other stresses that are associated with tumour growth (such as growth factor withdrawal, nutrient deprivation and acidosis) activate p53, which is a crucial tumour suppressor that is mutated or silenced in most human cancers 117 . Although it is maintained at low levels in normal cells by MDM2mediated ubiquitylation and subsequent proteasomal degradation, p53 is post translationally modified and stabilized in response to numerous stimuli, including abnormal proliferation sig nals, osmotic stress, DNA damage and hypoxia 118 . p53 forms homotetramers that bind and regulate numerous 
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genes that are involved in metabolism, DNA repair, cell cycle arrest and cell death, thus resulting in a coordinated cellular response to microenvironmental stress 117 . HIF1α and HIF2α have opposing effects on the p53 pathway. Numerous studies have shown that p53 accu mulation occurs within hypoxic regions of solid tumours and correlates with apoptosis, although this might only occur when also accompanied by acidosis and nutrient deprivation 119 . An et al. 120 originally suggested that tran scriptionally active wildtype p53 is stabilized through a physical association with HIF1α. SanchezPuig et al. 121 further reported that the HIF1α O 2 dependent degrada tion domain (ODD) and NTAD domain bind to p53 tetramers under physiological conditions; however, subsequent reports suggested that MDM2 mediates the interaction between p53 and HIF1α by acting as a bridge between the two transcription factors 122 . Whereas HIF1α fails to bind p53 in vitro, it directly binds MDM2, which suppresses the MDM2dependent ubiquityl ation of p53 in vivo and p53 nuclear export. Surprisingly, MDM2 overexpression promotes p53 accumulation and the transcription of p53 target genes when HIF1α is activated in hypoxic cells 122 . Furthermore, HIF1α seems to enhance the activation of p53 by ionizing radiation, which results in increased phosphorylation of p53 and increased p53mediated apoptosis 123 . Ionizing radia tion substantially increases HIF1α activity in tumours owing to increased concentrations of ROS and reac tive nitrogen species, and ionizing radiation combined with hypoxia leads to increased p53 phosphorylation in a HIF1αdependent manner by a mechanism that remains unclear.
It should also be noted that the relationship between HIF1α and p53 provides a potential negative feed back loop for HIF1α activity. Ravi et al. 124 suggested that p53 can induce HIF1α turnover by promoting MDM2mediated ubiquitylation and proteasomal deg radation of HIF1α. Moreover, they showed that deletion of TP53 in colon cancer cells increased HIF1α levels and augmented VEGFA expression and tumour angiogenesis, suggesting that inactivating p53 mutations can contribute to the 'angiogenic switch' during colorectal tumorigenesis.
In contrast to HIF1α, HIF2α does not bind MDM2 (REF. 125 ), and seems to inhibit p53 indirectly by mul tiple mechanisms. Bertout et al. 125 demonstrated that increased HIF2α expression inhibits p53 phosphory lation and stabilization in RCC cell lines, whereas knocking down HIF2α expression increased p53 transcriptional activity and target gene expression. Furthermore, HIF2αdeficient cells exhibit increases in DNA double strand break formation, ATM activity and ROS concentrations after ionizing radiation. HIF2α has been reported to regulate antioxidant enzymes, such as superoxide dismutase 1 (SOD1), SOD2, glutathione per oxidase 1 (GPX1) and catalase, in developing embryos and neonates 41 . However, in RCC cells, HIF2α instead decreases the accumulation of ROS by regulating the expression of other antioxidant enzymes, including haem oxygenase 1 (HMOX1), ceruloplasmin, GPX8 and peroxiredoxin 3 (PRDX3). Importantly, HIF2α expression in RCC tumour samples correlated with decreases in p53 phosphorylation and p53 target gene expression, and may contribute to radioresistance in HIF2αexpressing RCCs 125 . In parallel studies, Roberts et al. 126 showed that HIF2α also suppresses p53 expression and function through indirect effects on MDM2. AKTmediated phosphorylation of MDM2 promotes its nuclear locali zation and thus enhances p53 degradation; this repre sents an important prosurvival effect of AKT. AKT activation occurs downstream of growth factor recep tors such as epidermal growth factor receptor (EGFR) and plateletderived growth factor receptor (PDGFR). These receptors are stimulated by transforming growth factorα (TGFα) and PDGFβ, which are transcriptional targets of HIF2α in RCC cells. Thus, HIF2α overexpres sion in VHLdeficient RCC can inhibit p53 through a growth factor receptor-AKT-MDM2 pathway, in addi tion to maintaining redox homeostasis. In aggregate, these findings suggest that HIF2α probably contributes to RCC tumour cell survival during both ionizing radia tion exposure and chemotherapy treatment by multiple mechanisms.
HIFs regulate mTOR. Cell division requires high levels of protein synthesis and anabolic metabolism, which is regulated by the serine/threonine kinase mTOR in response to nutrient and growth factor availabil ity. mTORC1 promotes ribosome biogenesis, mRNA translation and nutrient import, while inhibiting autophagy 127 . Increased mTORC1 activity is observed in most human tumours owing to the activation of upstream oncogenes (such as PI3K or AKT) and/or the loss of tumour suppressors (such as PTEN or liver kinase B1 (LKB1; also known as STK11)) 128 . In particu lar, the tuberous sclerosis proteins, TSC1 and TSC2, together inhibit mTORC1 activity to limit cell growth under conditions of environmental stress, including reduced levels of growth factors, glucose, amino acids and O 2 (REF. 127 ).
Hypoxia suppresses mTORC1 through multiple mechanisms. For example, decreased ATP levels in severely hypoxic cells activate AMPactivated pro tein kinase (AMPK) 129 , which phosphorylates TSC2 (as well as the mTORC1associated factor, regulatory associated protein of mTOR (RAPTOR)) to inhibit mTORC1 activity. In addition, HIF1α (but not HIF2α) induces the expression of DNAdamageinducible tran script 4 (DDIT4) 130 , encoding REDD1, which represses mTORC1 by promoting the release of sequestered TSC2 from 1433 proteins 131 . Finally, the hypoxiainducible proautophagic protein BNIP3 binds and inhibits RAS homologue enriched in brain (RHEB), thus resulting in decreased mTORC1 activity 132 . HIF1αdependent inhi bition of mTORC1 might benefit cells by reducing ATP intensive protein synthesis while increasing autophagy under conditions of hypoxic stress.
By contrast, growing evidence suggests that HIF2α might stimulate mTORC1 to promote cellular prolifera tion in O 2 deprived cells. RB1inducible coiledcoil 1 (RB1CC1; also known as FIP200) has been identified as a HIF2α target gene through microarray studies 27 , and RB1CC1 has been proposed to interact with TSC1, thereby disrupting TSC1-TSC2 complexes and promot ing mTORC1 activation 133 . In addition, RB1CC1 may promote the degradation of TSC1 by the ubiquitinproteasome pathway 134 . HIF2α could also selectively enhance mTORC1 activity by positive effects on growth factor signalling, as HIF2α induces the expression of TGFα, PDGFβ and insulinlike growth factor 1 (IGF1), leading to the activation of AKT and mTORC1 in RCC cells 126 . Although additional work is clearly needed to further elucidate the molecular mechanisms by which HIF2α promotes mTORC1 functions, these results reveal another example of how HIF1α and HIF2α antag onize one another to balance hypoxic responses in key growthregulatory pathways.
HIFα and growth control. Why would the two HIFα subunits result in opposite effects on the MYC, p53 and mTORC1 pathways? The inhibitory activities of HIF1α towards these growthregulatory systems represent important mechanisms of energy conservation when ATP production is decreased during periods of limited O 2 availability. These conditions are likely to be com pounded by a decreased availability of nutrients (such as glucose, amino acids and lipids) and growth factors in hypoxic regions of solid tumours. By contrast, the pro growth effects of HIF2α might contribute to the ability of endothelial cells to proliferate during neoangiogenesis in ischaemic tissues. It is interesting that HIF2α accumulates at higher O 2 concentrations than HIF1α, which might allow its selective activation in blood vessels. In addition, the ability of HIF2α to promote cell growth in RCCs could explain why HIF1α expression is often silenced in these tumours. For example, focused 135 and genomewide 136 sequence and copy number analyses have identified trun cating HIF1A mutations in a small percentage of RCCs, as well as HIF1A heterozygosity in others 137 , supporting the hypothesis that inhibition of HIF1α function is a selective advantage for some RCCs. It is also tempting to specu late that the recent identification of EPAS1 single nucleo tide polymorphisms (SNPs) as a predisposing factor for RCC development 138 could reveal genetic alterations that increase or expand HIF2α function.
Therapeutic implications
As HIF complexes are instrumental in the adaptation of cancer cells to hypoxic tumour microenvironments, the ability to selectively inhibit HIF activity would seem to be of clinical benefit 1, 139 . Historically, DNAbinding pro teins have been difficult to target, but many compounds have been reported to inhibit HIF transcriptional activ ity, either directly or indirectly. For example, compounds that poison topoisomerase I (such as camptothecin and topotecan) 140 and DNA intercalators (for example, echinomycin, which intercalates at HRE sequences, and daunorubicin and doxorubicin, which are topo isomerase II poisons) 141 block HIF heterodimeriza tion and transcriptional activation, and interfere with xenograft tumour growth in a HIFdependent manner. These observations are particularly interesting, given the frequent use of these DNA damaging agents in chemotherapy. Oncogenic signal transduction pathways also promote mTORC1dependent HIF1A translation; consequently, inhibitors of receptor tyrosine kinases (such as trastuzumab, imatinib, erlotinib and gefitinib) and mTOR inhibitors (such as rapamycin, temsirolimus and everolimus) 142, 143 are thought to reduce tumour angiogenesis, and possibly other responses to hypoxia, by indirectly reducing the synthesis of HIFα subunits. Other drugs have been shown to increase HIFα degra dation, including HDAC inhibitors 144, 145 and compounds that disrupt the binding of HIFα proteins to HSP90 (REFS 146, 147) . These studies indicate that HIF activ ity is susceptible to inhibition using various drugs that are already approved for cancer treatment; however, the extent to which these drugs could limit the growth and progression of autochthonous tumours by specifically inhibiting HIF activity is as yet unknown, and needs to be investigated.
Given the disparate effects of HIF1α and HIF2α on tumour growth and progression described in this Review, it will also be crucial to determine whether potential HIF inhibitors affect both HIF1α and HIF2α equally. There could be situations in which selective inhibition of only HIF1α or HIF2α would be especially beneficial; for example, inhibiting HIF1α might be particularly advantageous for highly glycolytic hypoxic tumours, whereas inhibiting only HIF2α is likely to be useful for treating RCCs. Intriguingly, Iliopoulos and colleagues 62 identified a series of small compounds that interfere with the translation of EPAS1 mRNA by enhancing the binding of IREBP1 to the IRE that is found in the 5′ UTR of EPAS1, but not in HIF1A. Selective agents of this kind could be particularly useful in cancers that express both HIF1α and HIF2α, but in which the iso forms have distinct roles. Furthermore, Dewhirst and colleagues 148 have shown that ionizing radiation induces the expression of HIF1α and VEGFA, which protects endothelial cells from ionizingradiationmediated apo ptosis. The treatment of tumourbearing mice with the HIF inhibitor YC1 enhanced blood vessel destruction and slowed tumour growth; in another study 148 , the HIF inhibitor PX478 reduced VEGFA expression, render ing xenografts more sensitive to ionizing radiation. As stated previously, endothelial VEGFA expression seems to be regulated primarily by HIF1α, suggesting that the selective inhibition of HIF1α would be beneficial.
Finally, HIF inhibition could be advantageous only up to a certain point. As discussed earlier, the over expression of HIF2α, as well as the deletion of EPAS1, increases the growth of KRASdriven lung tumours in mice, although by different mechanisms. Too much HIF2α increases the expression of VEGFA and SNAIL, thus promoting angio genesis and tumour invasion. By contrast, the complete loss of HIF2α reduces the expression of the tumour sup pressor Scgb3a1, a HIF2α target gene. These data indicate that inhibition of HIF proteins might involve a nar rower therapeutic window than was initially envisioned. Although currently in early stages of development, the prospect of pharmacological inhibition of HIF proteins for cancer treatment, whether targeting HIF1α and HIF2α together, or either subunit individually, is an exciting one.
